Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone  8% gel and Utrogestan  capsules, used for luteal support

Šimunić, Velimir; Tomić, Vlatka; Tomić, Jozo; Nizić, Dinko

doi:10.1016/j.fertnstert.2006.05.067

Cited by 56 publications

(51 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is more convenient for patients and allergic reactions are rare. Comparing Utrogestan and Crinone 8%, there were no differences in efficiency though patients prefer Crinone 8% for better tolerance 29,30 . For luteal support, vaginal P is therefore the first method of choice.…”

Section: Discussionmentioning

confidence: 90%

Vaginal use of micronized progesterone for luteal support.A randomized study comparing Utrogestan® and Crinone® 8%

Michnová

Dostál²,

Kudela³

et al. 2017

BIOMED PAP

View full text Add to dashboard Cite

Background and Objective. Luteal phase physiology is distorted by in vitro fertilization (IVF) cycles using gonadotropin-releasing hormone (GnRH) agonists and antagonists, Controlled ovarian hyperstimulation leads to luteal phase defect and for this reason, luteal phase support is now an integral part of IVF/ICSI-ET programs. The support is provided by hCG, progesterone or GnRH-a. This study compared the efficiency, safety and tolerance of two vaginal micronized progesterones, Utrogestan and Crinone 8%. Methods. 111 women, 18-40 years old, FSH < 10 IU/L and normal uterus findings were included. The efficiency of the two preparations to provide luteal support was evaluated by the fertilization, implantation, pregnancy and take-home baby rates. The safety was compared through the results of vaginal findings and vaginal inflammation markers before and after treatment. Comparison of tolerance was made by evaluating 21 subjective patient questionnaire parameters.Results. There were no significant differences between the preparations in terms of efficiency or safety though Crinone 8% was better tolerated. Conclusion. The outcomes of this study suggest that a vaginal gel with micronized progesterone (Crinone 8%) is the optimal choice at this time for luteal support.

show abstract

Section: Discussionmentioning

confidence: 90%

Vaginal use of micronized progesterone for luteal support.A randomized study comparing Utrogestan® and Crinone® 8%

Michnová

Dostál²,

Kudela³

et al. 2017

BIOMED PAP

View full text Add to dashboard Cite

show abstract

“…It suggested that initiating LPS treatment on either hCG day, oocyte retrieval day or embryo transfer day makes no difference as far as the ongoing pregnancy rates are concerned (respectively 20.8%, 22.7% and 23.6%) [7]. The general global approach to LPS in IVF treatments has been to use vaginal progesterone, particularly vaginal gel, due to its minimal side-effect spectrum and ease of application [24][25][26][27][28]. However, studies comparing different vaginal progesterone formulations with regard to IVF success did not go beyond a limited number [24][25][26][27][28][29][30].…”

Section: Discussionmentioning

confidence: 99%

“…The general global approach to LPS in IVF treatments has been to use vaginal progesterone, particularly vaginal gel, due to its minimal side-effect spectrum and ease of application [24][25][26][27][28]. However, studies comparing different vaginal progesterone formulations with regard to IVF success did not go beyond a limited number [24][25][26][27][28][29][30]. Detailed analysis of the available literature revealed a very limited number of studies investigating the differences of the vaginal forms, except for two recent large randomized trials [28,30].…”

Section: Discussionmentioning

confidence: 99%

Progesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles

Gün

Özdamar²,

Şahin³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

Objectives: The aim of the study was to investigate the effects of two different vaginal progesterone forms, administered for luteal phase support, on pregnancy outcomes in normoresponder women aged < 35, who underwent long agonist IVF/ICSI-ET cycles. Material and methods:A retrospective cohort analysis was designed. Normoresponders with primary infertility, who underwent IVF/ICSI-ET cycles employing GnRH analogue and who received progesterone as either capsule or gel form for LPS following a single embryo transfer, were analyzed. The cycles were categorized into two groups: micronized progesterone vaginal capsule 600 mg/day (Group 1, n = 78) and progesterone vaginal gel 180 mg/day (Group 2, n = 99). Positive β-hCG, clinical pregnancy and ongoing pregnancy rates were analyzed.Results: Both, demographic and stimulation characteristics were comparable between the groups. No difference was observed between the capsule and the gel groups regarding positive β-hCG (33.3% and 28.3%, respectively; p = 0.580), clinical pregnancy (26.9% and 22.2%, respectively; p = 0.584), and ongoing pregnancy rates (21.8% and 20.2%, respectively; p = 0.942) after treatment completion. Conclusions:In long agonist IVF/ICSI-ET cycles, positive β-hCG, clinical pregnancy and ongoing pregnancy rates do not significantly differ between normoresponder patients receiving micronized progesterone vaginal capsule and those receiving progesterone vaginal gel for LPS.

show abstract

“…A study evaluating the use of 100-mg progesterone capsules (200 mg vaginal every 8 h) and progesterone gel 8% (90 mg vaginal every 24 h) showed that both treatments had similar efficacy; however, the gel had a lower incidence of local adverse reactions than capsules, and the tolerability and acceptability was superior for the progesterone gel [13]. …”

Section: Discussionmentioning

confidence: 99%

Observational Study of the Local Tolerability of Injectable Progesterone Microspheres

Bernardo-Escudero

Cortés-Bonilla²,

Alonso-Campero³

et al. 2011

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background: As intramuscular progesterone administration is associated with local intolerance, the purpose of this work was to determine the local tolerability of a new progesterone microsphere suspension, administered by intramuscular injection. Methods: An observational, longitudinal, prospective, analytical, multicenter, active pharmacovigilance study was conducted. Two hundred and seven progesterone microsphere administrations were evaluated. Patients evaluated pain, burning sensation, pruritus and dysesthesia. Physicians evaluated erythema, pallor, petechia, ecchymosis, bleeding, edema, induration, abscess, macule, papule, vesicle and pustule. Local tolerability was evaluated using a visual analog scale (100-mm line) on the day of administration, and subsequently on days 3 and 7. Local symptoms were evaluated by patients and local signs by the attending physicians. Results: On the day of application, 68.4% of the administered doses were associated with ‘absent’ or ‘mild’ pain, rising to 91.2% on the 7th day; 83.0% of doses were associated with ‘absence’ of or a ‘mild’ burning sensation on the day of administration, rising to 99.5% on day 7. On administration day, 13.2% reported ‘mild’ erythema and 1.0% ‘moderate’ erythema, and 3.9% of doses had ‘mild’ induration and 0.5% ‘moderate’ induration, which increased to 16.6 and 2.9% on day 3, respectively. The values for pallor, ecchymosis, bleeding, edema and pustule were lower than 10 mm (of 100 mm) on the application day and behaved similarly in subsequent days. There were no reports of petechia, abscess, macule, papule or vesicle with the dose application. Conclusions: Progesterone microspheres were well tolerated without serious or unexpected adverse effects.

show abstract

Comparative study of the efficacy and tolerability of two vaginal progesterone formulations, Crinone 8% gel and Utrogestan capsules, used for luteal support

Cited by 56 publications

References 36 publications

Vaginal use of micronized progesterone for luteal support.A randomized study comparing Utrogestan® and Crinone® 8%

Vaginal use of micronized progesterone for luteal support.A randomized study comparing Utrogestan® and Crinone® 8%

Progesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles

Observational Study of the Local Tolerability of Injectable Progesterone Microspheres

Contact Info

Product

Resources

About